55
Participants
Start Date
January 31, 2010
Primary Completion Date
August 31, 2014
Study Completion Date
August 31, 2014
humanised monoclonal antibody, veltuzumab
Veltuzumab with modified UKALL XII induction chemotherapy. Veltuzumab will be administered at 200 mg/m2 IV on Day 8 and subsequently, (if tolerated on Day 8), over 1 hour on Days 15, 22, 29.
humanised monoclonal antibody epratuzumab
Epratuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.
humanised monoclonal antibodies veltuzumab and epratuzumab
Epratuzumab + Veltuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29. Veltuzumab will be administered at 200 mg/m2 IV over 2 hours on Day 8 and over 1 hour on Days 15, 22 and 29. Veltuzumab will be infused 1 hour after the infusion of epratuzumab.
University Hospitals Birmingham NHS Foundation, Birmingham
University of Bristol Foundation Trust, Bristol
University Hospital of Wales, Cardiff
Beatson West of Scotland Cancer Centre, Glasgow
Leeds Teaching Hospitals NHS Trust, Leeds
Barts and the London NHS Trust, London
Royal Free Hampstead NHS Trust, London
Newcastle University, Newcastle
Nottingham City Hospital, Nottingham
Plymouth Hospitals NHS Trust, Plymouth
Collaborators (1)
Gilead Sciences
INDUSTRY
Queen Mary University of London
OTHER